Ambroxol
Active ingredient description
Ambroxol induces activation of the surfactant system by acting directly on the type II pneumocytes of the alveoles and the Clara cells in the region of the small airways. It promotes the formation and outward transfer of surface-active material in the alveolar and bronchial region of the foetal and adult lungs.
Medicine classification
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Medicines
Ambroxol is the active ingredient of these drugs:
Tunisia
Poland
Estonia Lithuania
Austria
Germany
Tunisia
Austria Germany Poland
Brazil
Austria Estonia Lithuania
Estonia Poland
Hong Kong
Lithuania Poland
Lithuania
Lithuania
Brazil
Hong Kong
Hong Kong
Hong Kong
Hong Kong
Hong Kong Singapore
Spain
Hong Kong
Hong Kong Singapore
Brazil
Estonia Lithuania
Brazil
Lithuania
Spain
Poland
Spain
Poland
Poland
Hong Kong
Brazil
Estonia Finland Lithuania Poland
Poland
Brazil Cyprus
Brazil
Hong Kong
Poland
Poland
Lithuania
Cyprus
Estonia Lithuania
Hong Kong
Cyprus
Cyprus Hong Kong
Spain
Hong Kong
Hong Kong
Spain
Austria Germany Netherlands Poland South Africa
Hong Kong
Cyprus
Singapore
Hong Kong
Brazil
Austria Spain
Austria Brazil Cyprus Germany Hong Kong
Brazil
Brazil
Brazil
Spain
France Tunisia
Hong Kong
Poland
Brazil
Poland
Singapore
Estonia
Brazil
Hong Kong
Brazil
Singapore
Brazil
Hong Kong Singapore
France Tunisia
Hong Kong
Poland
Hong Kong
Germany
Ambroxol is also found within below combination drugs:
Product monographs
Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):
Structural formula
Unique ingredient identifier (UNII)
200168S0CL - AMBROXOL
CAS registry number
18683-91-5 - ambroxol
SNOMED-CT
698024002 - Ambroxol (substance)